ArticleJournal of cancer research and clinical oncology2020

Selected ellipticine derivatives, known to target topoisomerase II, suppress the alternative lengthening of telomere (ALT) pathway in telomerase-negative cells.

Sevil Zencir et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.